Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 5Neoplasm Metastasis 4Lung Neoplasms 4Adenocarcinoma 3Stomach Neoplasms 2Pancreatic Diseases 2Neoplasms by Site 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Carcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Pericardial Effusion 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Non-Small-Cell Lung 1Non Small Cell Lung Cancer NSCLC 1Neuralgia 1Neoplasms, Unknown Primary 1

Interventions

Paclitaxel 1NOV 002 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pericardial Effusion × Albumin-Bound Paclitaxel × Clear all
NCT00347412 2022-07-25

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Cellectar Biosciences, Inc.

Phase 3 Completed
903 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pericardial Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡